PMN Form 3: Director lists 6,058,738 shares and warrant holdings

Q: What did ProMIS Neurosciences (PMN) disclose in this Form 3?

A director reported indirect beneficial ownership of 6,058,738 common shares and several warrant positions, as of 10/22/2025 .

Q: How many PMN common shares does the reporting person own?

The filing lists 6,058,738 common shares , reported as indirect ownership.

Q: What derivative securities are included in the report?

Warrants for 7,348,604 shares at $1.25 expiring 07/29/2030 , and warrants for 1,066,674 shares at $1.75 expiring 02/28/2029 , plus additional $0.01 warrants.

Q: What is the nature of the indirect ownership reported?

Securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ; the reporting person disclaims beneficial ownership except to any pecuniary interest.

Q: Do any PMN warrants lack a fixed expiration date?

For entries marked “(2)”, the filing states the warrants will expire when exercised in full .

Q: What is the reporting person’s relationship to PMN?

The reporting person is a Director of PMN and an employee of Ally Bridge Group (NY) LLC .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ProMIS Neurosciences (PMN) director filed a Form 3 reporting indirect holdings. The filing lists 6,058,738 common shares beneficially owned indirectly, held of record by Ally Bridge MedAlpha Master Fund L.P. The reporting person is a director and an employee of Ally Bridge Group (NY) LLC and disclaims beneficial ownership except to any pecuniary interest.

Derivative holdings include warrants for 7,348,604 common shares at $1.25 expiring 07/29/2030 and warrants for 1,066,674 common shares at $1.75 expiring 02/28/2029. The filing also lists additional warrants including tranches exercisable at $0.01; for those marked “(2)”, the warrants will expire when exercised in full.

The event date is 10/22/2025, and the ownership is reported as indirect (I) with the nature of ownership described in the footnote.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Alex Slanix Paul

Role Director

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Warrants — 174,759 shares (Indirect, See Footnote); Common Shares — 6,058,738 shares (Indirect, See Footnote)

Footnotes (1)

These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. The Reporting Person is a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose. The warrants will expire when exercised in full.

Understanding Insider Trading Forms →

10/24/2025 - 04:30 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Alex Slanix Paul

(Last)

(First)

(Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO

M4S 3E2

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2025

3. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	6,058,738	I	See Footnote⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants	08/28/2023	⁽²⁾	Common Shares	174,759	$0.01	I	See Footnote⁽¹⁾
Warrants	02/28/2024	02/28/2029	Common Shares	1,066,674	$1.75	I	See Footnote⁽¹⁾
Warrants	07/26/2024	⁽²⁾	Common Shares	1,100,000	$0.01	I	See Footnote⁽¹⁾
Warrants	07/29/2025	07/29/2030	Common Shares	7,348,604	$1.25	I	See Footnote⁽¹⁾

Explanation of Responses:

1. These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. The Reporting Person is a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.

2. The warrants will expire when exercised in full.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Max A. Milbury, Attorney-in-Fact	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ProMIS Neurosciences (PMN) disclose in this Form 3?

A director reported indirect beneficial ownership of 6,058,738 common shares and several warrant positions, as of 10/22/2025.

How many PMN common shares does the reporting person own?

The filing lists 6,058,738 common shares, reported as indirect ownership.

What derivative securities are included in the report?

Warrants for 7,348,604 shares at $1.25 expiring 07/29/2030, and warrants for 1,066,674 shares at $1.75 expiring 02/28/2029, plus additional $0.01 warrants.

What is the nature of the indirect ownership reported?

Securities are held of record by Ally Bridge MedAlpha Master Fund L.P.; the reporting person disclaims beneficial ownership except to any pecuniary interest.

Do any PMN warrants lack a fixed expiration date?

For entries marked “(2)”, the filing states the warrants will expire when exercised in full.

What is the reporting person’s relationship to PMN?

The reporting person is a Director of PMN and an employee of Ally Bridge Group (NY) LLC.